Phase III Trial for Patients With mCSCC Who Progress After First-line Chemotherapy
Danny Rischin, MD, MBBS, FRACP, discusses an ongoing phase III trial for patients with metastatic cutaneous squamous cell carcinoma or recurrent disease after progressing on frontline chemotherapy.
Danny Rischin, MD, MBBS, FRACP, director, division of cancer medicine, and head, department of medical oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses an ongoing phase III trial for patients with metastatic cutaneous squamous cell carcinoma or recurrent disease after progressing on frontline chemotherapy.
These patients are usually treated with a platinum-Taxol and bevacizumab (Avastin), but there are very few options after that, Rischin says. Survival rates after progression have also been very poor.
Recent Videos
Related Content
